Mallinckrodt Inc

Mallinckrodt — Merger or Acquisition (August 2015)

11 slides from Mallinckrodt's merger presentation, Aug 11, 2015

  1. Slide 1: Mallinckrodt Strategic Acquisition: Therakos, Inc.

    Exhibit 99.1 Mallinckrodt Strategic Acquisition Therakos, Inc. August 11, 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements in this document that are not strictly historical, including statements regarding, the proposed acquisition of Therakos, Inc., the expected timetable for completing the transaction, future financial condition and operating results, economic, business, competitiv

  3. Slide 3: Forward-Looking Statements (continued)

    Forward-Looking Statements (continued) Mallinckrodt’s reliance on certain individual products that are material to its financial performance; Cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; The reimbursement practices of a small number of

  4. Slide 4: Mallinckrodt to acquire Therakos, Inc. for $1.325B

    Mallinckrodt to acquire Therakos, Inc. for $1.325B Therakos adds value to Mallinckrodt Advances Mallinckrodt’s growth strategy Increases depth in Specialty Brands; further diversifies Hospital portfolio ECP 1,2 immunotherapy treatment used in cancer, transplant, GvHD³, Crohn’s disease, delivered in

  5. Slide 5: Transaction highlights

    Transaction highlights Consideration Acquisition of Therakos for approximately $1.325 billion Expected to be accretive by no less than $0.10 per share to adjusted diluted fiscal 2016 earnings and increasingly accretive thereafter¹ Therakos With roughly 60% of revenue in U.S., we expect fiscal 2015 n

  6. Slide 6: Used globally in T-cell mediated diseases

    Used globally in T-cell mediated diseases – CTCL¹, GvHD, solid organ transplant, Crohn’s disease Razor/Razor Blade Model • Average 25-40 treatments/year per patient ® • One vial of UVADEX and one sterile kit per treatment 3 Photoactivated white blood • Over 120,000 treatments globally in 2014 cells

  7. Slide 7: Global franchise driven by U.S. growth

    Global franchise driven by U.S. growth ROW 3% Widely trusted treatment: Broad global label 10+ years clinical experience Broadly reimbursed: Europe North U.S. DRG 35% America Stable reimbursement ex-U.S. 62% Strong competitive position: Large installed base 322 active global patents and applications

  8. Slide 8: Low current penetration, large market potential

    Low current penetration, large market potential Total Global Eligible ECP CTCL U.S. Patient Population 4 Patient Population CTCL ~23,000 2 Prevalence (~20,000) Refractory Patients (~2,400) 1 ~3,000 ECP Treated 3 Treated Eligible (~400) 1Current global treated patients includes promoted and not promo

  9. Slide 9: Significant label expansion opportunity supported by 10+ years of safety data

    Significant label expansion opportunity supported by 10+ years of safety data Indication(s) Preclinical Phase 1 Phase 2 Pivotal Approved EU/ Photopheresis AUS Administration U.S. CTCL Canada Scleroderma Japan Chronic GvHD¹ Acute GvHD¹ U.S./ Chronic GvHD LatAm Other Indications (e.g., Cystic Fibrosis

  10. Slide 10: Mallinckrodt is the best owner of Therakos

    Mallinckrodt is the best owner of Therakos 1 Differentiated Only FDA-approved closed ECP system product Highly durable asset with opportunity for near-term expansion expands Large, established base, 800+ devices, 350+ hospitals, 25+ countries existing Broad global reimbursement franchises Mallinckro

  11. Slide 11: Therakos continues Mallinckrodt's development of a diversified, durable, high-value portfolio

    Therakos continues Mallinckrodt’s development of a diversified, durable, high-value portfolio Key Value Drivers Performance Objective • Expand system placement, kit/drug volume • High single-digit revenue growth • Label expansion 1 • >$500 million net sales • Clinical, HEOR data generation/dissemina

Mallinckrodt — Merger or Acquisition (August 2015) on 6ix